Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Genmab (GMAB) Stock Price & Analysis
488 Followers
GMAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$24.53 - $42.72
Previous Close$25.15
Volume127.05K
Average Volume (3M)498.63K
Market Cap
$16.80B
Enterprise Value$12.65B
Total Cash (Recent Filing)kr28.14B
Total Debt (Recent Filing)kr770.00M
Price to Earnings (P/E)20.7
Beta0.76
Next Earnings
Aug 01, 2024EPS Estimate
$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding660,745,350
10 Day Avg. Volume639,054
30 Day Avg. Volume498,632
Standard Deviation0.10
R-Squared0.30
Alpha0.00039
Financial Highlights & Ratios
Price to Book (P/B)0.55
Price to Sales (P/S)1.04
Price to Cash Flow (P/CF)2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$50.00Price Target Upside96.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Genmab News
PremiumCompany Announcements
Genmab’s Epcoritamab Poised to Transform Lymphoma Treatment
PremiumCompany Announcements
Genmab Completes Share Buy-back Program Early
PremiumPress Releases
Completion of Share Buy-back Program
PremiumCompany Announcements
FDA Approves Genmab’s Innovative Lymphoma Treatment
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEpkinly's promising outcomes, including an overall response rate of 82% and a complete response rate of 63%, underscore its potential to provide durable responses for patients facing limited therapeutic options post-relapse.
Market CompetitivenessEpkinly has beaten Lunsumio to the market and its promising results suggest that it will be used for late-line follicular lymphoma patients in the post-Lunsumio setting.
Regulatory ApprovalThe FDA has granted accelerated approval to Epkinly for the treatment of adult patients with relapsed or refractory follicular lymphoma.
Bears Say
Clinical DataThere are acknowledged risks associated with overinterpreting the overall survival data and concerns regarding liver toxicity.
Product SalesRisks include slowing DARZALEX sales and failure to obtain DARZALEX label extensions.
Research And DevelopmentThe acasunlimab results are considered a high-risk program due to the small sample set.
---
Ownership Overview
0.00%
Insiders
1.85% Mutual Funds
0.88% Other Institutional Investors
97.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $24.53 and its highest was $42.72 in the past 12 months.
What is Genmab A/S’s market cap?
Currently, no data Available
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Aug 01, 2024 which is in 27 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on May 02, 2024. The company reported $0.291 earnings per share for the quarter, beating the consensus estimate of $0.186 by $0.105.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is $0.3.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 661,369,100 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.291 in its last earnings report, beating expectations of $0.186. Following the earnings report the stock price went down -3.583%.
Which hedge fund is a major shareholder of Genmab A/S?
Among the largest hedge funds holding Genmab A/S’s share is Gallacher Capital Management LLC. It holds Genmab A/S’s shares valued at 235K.
---
Genmab Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.00 (96.35% Upside)
$50.00 (96.35% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 196.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.09%
12-Months-Change
Fundamentals
Return on Equity
18.32%
Trailing 12-Months
Asset Growth
19.81%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
---
GMAB Company Deck
---
GMAB Earnings Call
Q1 2024
0:00 / 0:00
---
GMAB Stock 12 Month Forecast
Average Price Target
$50.00
▲(96.35% Upside)
Technical Analysis
Best Analysts Covering GMAB
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-11.47%
reiterated a buy rating last month
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -11.47% per trade.
---